Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Investigating the role of different macrophage phenotypes on responses to immunotherapy in colorectal cancer subsets
EF 2023-24
Résumé
Colorectal cancer (CRC) is influenced by the tumor microenvironment (TME) which is composed of many cell types, including macrophages. Traditionally, tumor-resident macrophages have been linked to cancer progression and poor response to treatment. However, recent findings have found different phenotypes of macrophages can lead to different responses. Proinflammatory M2-type macrophages have often been seen to be pro-tumorigenic, while M1-type macrophages are more anti-tumorigenic.
In CRC, the microsatellite instable (MSI) subtype responds well to anti-PD1 therapy, which is known for preventing T-cell exhaustion, while the chromosomally instable (CIN) subtype typically does not. This study aims to explore how different macrophage phenotypes in the CRC TME impact their response to immunotherapy, such as anti-PD1 therapy, and patient survival.
Using CRC cell lines and mouse models, we will investigate how MSI and CIN tumors influence macrophage phenotypes and the response to anti-PD1 therapy. Human CRC organoids will be used by creating autologous co-cultures with patient-derived macrophages and tumor-specific T cells in the presence of anti-PD1 antibodies.
Given that CRC is a prevalent cancer in Canada, this research is crucial for understanding why certain CRC subtypes respond poorly to immunotherapies and aims to contribute to the development of more effective treatments.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506520
Name
Morris Kayleigh A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of different macrophage phenotypes on responses to immunotherapy in colorectal cancer subsets
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive T Cell Transfer; Anti-Pd1 Therapy; Colon; Colorectal Cancer; Immunology; Immunotherapy; Innate Immunity; Macrophages; Oncology; Organoids
Abstract
Colorectal cancer (CRC) is influenced by the tumor microenvironment (TME) which is composed of many cell types, including macrophages. Traditionally, tumor-resident macrophages have been linked to cancer progression and poor response to treatment. However, recent findings have found different phenotypes of macrophages can lead to different responses. Proinflammatory M2-type macrophages have often been seen to be pro-tumorigenic, while M1-type macrophages are more anti-tumorigenic.
In CRC, the microsatellite instable (MSI) subtype responds well to anti-PD1 therapy, which is known for preventing T-cell exhaustion, while the chromosomally instable (CIN) subtype typically does not. This study aims to explore how different macrophage phenotypes in the CRC TME impact their response to immunotherapy, such as anti-PD1 therapy, and patient survival.
Using CRC cell lines and mouse models, we will investigate how MSI and CIN tumors influence macrophage phenotypes and the response to anti-PD1 therapy. Human CRC organoids will be used by creating autologous co-cultures with patient-derived macrophages and tumor-specific T cells in the presence of anti-PD1 antibodies.
Given that CRC is a prevalent cancer in Canada, this research is crucial for understanding why certain CRC subtypes respond poorly to immunotherapies and aims to contribute to the development of more effective treatments.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Morris, Kayleigh A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~